睿知中国医院研究地图
候选清单

正在招募胰腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

ClinicalTrials.gov 上登记的一项胰腺癌开放试验。牵头方不是本站收录的医院;本站收录的 5 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 5

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
  2. 研究中心上海交通大学医学院附属仁济医院Renji Hospital上海医院页面
  3. 研究中心同济大学附属东方医院Shanghai East Hospital, Tongji University上海医院页面
  4. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
  5. 研究中心四川大学华西医院West China Hospital成都医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06111274,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Diagnosis as non resectable local advanced or metastatic pancreatic cancer by histology or cytology.

    入选标准第 2 条

  3. Previous treatment with highly selective inhibitors targeting Colony Stimulating Factor 1 (CSF-1)/Colony Stimulating Factor 1 Receptor (CSF-1R).

    排除标准第 2 条

    Surgical treatment is required within 4 weeks before the first administration, or unhealed, infected, or dehiscence of previous surgical wounds.

    排除标准第 7 条

    During the 2 weeks prior to the first administration of this study, the patient was receiving chronic systemic steroid treatment or any other form of immunosuppressive treatment.

    排除标准第 8 条

  4. ECOG physical strength score 0-2

    入选标准第 5 条

  5. Measurable disease as defined by RECIST 1.1.

    入选标准第 3 条

  6. With Breast Cancer Gene 1/2 (BRCA1/2) gene mutation.

    排除标准第 3 条

    With a history of other malignancies within 5 years.

    排除标准第 4 条

  7. Pregnant or lactating women.

    排除标准第 19 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06111274,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Male and female aged 18-75 years old. The subjects must have informed consent to the study, and signed the written informed consent voluntarily.
  2. Diagnosis as non resectable local advanced or metastatic pancreatic cancer by histology or cytology.
  3. Measurable disease as defined by RECIST 1.1.
  4. Without systemic treatment for pancreatic cancer.
  5. ECOG physical strength score 0-2
  6. Estimated survival time >=3 months.
  7. The adequate bone marrow fuction and coagulation function

排除标准:Exclusion Criteria:

  1. Known allergy or hypersensitivity to any components of the investigational drug product.
  2. Previous treatment with highly selective inhibitors targeting Colony Stimulating Factor 1 (CSF-1)/Colony Stimulating Factor 1 Receptor (CSF-1R).
  3. With Breast Cancer Gene 1/2 (BRCA1/2) gene mutation.
  4. With a history of other malignancies within 5 years.
  5. During the trial, other chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy (except for local symptomatic radiotherapy) or traditional Chinese medicine must be used for anti-tumor treatment.
  6. With conditions that significantly affected the absorption of oral drug.
  7. Surgical treatment is required within 4 weeks before the first administration, or unhealed, infected, or dehiscence of previous surgical wounds.
  8. During the 2 weeks prior to the first administration of this study, the patient was receiving chronic systemic steroid treatment or any other form of immunosuppressive treatment.
  9. Concomitant use of strong inhibitors or inducers of Cytochrome P450 3A4 (CYP3A4) within 14 days prior to randomization.
  10. Previous peripheral neuropathy > grade 1 (Common Terminology Criteria for Adverse Events, version 5.0).
  11. Diagnosed with immune deficiency or interstitial lung disease.
  12. The patients were vaccinated within 4 weeks before the first treatment.
  13. Participated in any drug clinical trial within 4 weeks before the first treatment.
  14. Active central nervous system (CNS) metastases.
  15. Impaired cardiac function or clinically significant cardiac disease.
  16. Known active liver or biliary disease, or other diseases that may lead to abnormal liver function test results during the study.
  17. Known active infections from certain viruses, bacteria or parasites.
  18. Patients with refractory/uncontrolled ascites or pleural effusion.
  19. Pregnant or lactating women.
  20. Any other clinically significant comorbidities, which in the judgment of the Investigator, should not be included.

引自 ClinicalTrials.gov, NCT06111274, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06111274,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06111274